Related Experiment Video
Updated: Feb 22, 2026
08:50
Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
13.7K
Real-world experience with neuromuscular blockade reversal
Scott B Groudine1, Harold S Minkowitz2, Danny L Valentine3
1Professor of Anesthesiology and Surgery, Albany Medical Center, Albany, NY.
Journal of Clinical Anesthesia
|October 1, 2017
Summary
Neuromuscular blockade reversal agents, including neostigmine/glycopyrrolate and sugammadex, facilitate rapid reversal and reduce complications. Real-world cases demonstrate their significant impact on patient outcomes in diverse surgical settings.
Area of Science:
- Anesthesiology and Pharmacology
- Critical Care Medicine
Background:
- Neuromuscular blocking agents (NMBAs) are essential in modern surgery, enabling complex procedures.
- Residual neuromuscular blockade (RNB) can lead to significant postoperative complications.
- Pharmacologic reversal agents are crucial for safe and effective NMBA management.
Discussion:
- Neostigmine/glycopyrrolate and sugammadex are the primary agents for antagonizing NMBAs in the US.
- Sugammadex represents a newer option compared to the long-established neostigmine/anticholinergic combination.
- The choice of reversal agent impacts the speed and completeness of neuromuscular blockade reversal.
Key Insights:
- Real-world case studies illustrate the clinical utility of NMB reversal agents.
- Effective reversal agents contribute to improved patient outcomes across various surgical procedures.
- Timely and complete NMB reversal mitigates postoperative respiratory complications.
Outlook:
- Further research into optimizing NMB reversal strategies is warranted.
- The expanding availability of reversal agents enhances anesthetic care possibilities.
- Continued evaluation of sugammadex and neostigmine/glycopyrrolate in diverse clinical scenarios is essential.
Related Concept Videos
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.1K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.1K
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
831
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
831
01:19Depolarizing Blockers: Pharmocokinetics
628
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
628
01:28Depolarizing Blockers: Mechanism of Action
3.0K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.0K
01:29Neuromuscular Junction And Blockade
5.2K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.2K